Birchview Capital’s NovoCure NVCR Stock Holding History

Birchview Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-202,330	Closed	-$2.21M	–	78
2026 Q1	$2.21M	Buy	202,330 +50,230	+33%	+$627K	1.26%	21
2025 Q4	$1.97M	Buy	152,100 +50,000	+49%	+$642K	1.15%	23
2025 Q3	$1.32M	Buy	102,100 +1,100	+1%	+$14.7K	1%	26
2025 Q2	$1.8M	Buy	101,000 +70,000	+226%	+$1.22M	1.79%	16
2025 Q1	$552K	Hold	31,000	–	–	0.48%	31
2024 Q4	$924K	Buy	31,000 +11,000	+55%	+$233K	0.75%	24
2024 Q3	$313K	Hold	20,000	–	–	0.27%	44
2024 Q2	$343K	Buy	+20,000	New	+$352K	0.32%	41

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Birchview Capital's NVCR Position: Q2 2026 in Review

Birchview Capital sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 202,330 shares — an estimated $2.21M sold.

Birchview Capital first reported a position in NVCR in Q2 2024 and held it in 8 quarters. The position peaked at $2.21M in Q1 2026. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Birchview Capital reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Birchview Capital sold 202,330 NovoCure shares in Q2 2026, an estimated $2.21M.
Birchview Capital first reported a position in NovoCure in Q2 2024 and held it in 8 quarters.
Birchview Capital's NovoCure position peaked at $2.21M in Q1 2026.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.